On the one hand, hyperinsulinemia may enhance the bioavailability of IGF-1 and IGF-2 by inhibiting the synthesis of IGFBP-1/2 and promoting the production of IGF-1 in the liver [181]. The gene discussed is IGF1; the disease is Hyperinsulinemia.